Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2010

Stemgent to Supply Stem Cell Related Reagents from Pfizer

  • ChromoCure signed a letter of intent to acquire Genome Research Group (GRG). The merger transaction is valued to be in excess of $25 million. ChromoCure claims the combination of GRC’s platforms with its own chromosomal-scanning technology will strengthen its capabilities in cancer detection and therapy by providing on-demand, real-time cancer progression analysis to monitor treatment efficacy.

    GRG develops and provides cancer-detection systems and related therapeutic technologies. It claims that its Therapeutic Modeling Protocols are effective in detecting cancers at all stages. The firm has also developed therapeutic-modeling protocols and algorithms utilizing hypothermic modulation and resonance for the nontoxic and noninvasive treatment of cancer.

    ChromoCure develops technologies based on the chromosomal theory of cancer. The company has tools, designs, protocols, and algorithms for cancer detection. It says that it has also developed a platform that scans suspect cells for the presence or absence of the chromosomal condition common to all cancers at all stages. In addition to cancer detection the firm is also using its understanding of cancer’s chromosomal properties for the potential development of effective, nontoxic therapeutic strategies.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »